Hyperlipidemia Type 3 Treatments

Find Hyperlipidemia Type 3 Treatments

Generic Name

Pravastatin

FDA approval date: April 25, 2006

Classification: HMG-CoA Reductase Inhibitor

Form: Tablet

What is Pravastatin?

Pravastatin sodium tablets are indicated: Pravastatin sodium tablets are an HMG-CoA reductase inhibitor indicated : To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol without clinically evident coronary heart disease ., To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD., As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia., As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with:, Primary dysbetalipoproteinemia., Hypertriglyceridemia.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

TRADstat: Novel Treatment of Radiation Associated Dysphagia With Statins

Enrollment Status: Recruiting

Publish Date: March 03, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: The aim of this trial is to examine the feasibility, acceptability, and potential efficacy of a 12-month course of pravastatin as an antifibrotic agent for managing dysphagia (swallowing problems) in patients previously treated with radiotherapy for head and neck cancer (HNC). The purpose is to assess whether pravastatin, a medication approved in Australia for cholesterol management, can improve s...

Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing Daily Administration as a Treatment Strategy (STATIN-PRE Trial)

Enrollment Status: Recruiting

Publish Date: February 23, 2026

Intervention Type: Drug, Other

Study Phase: Phase 2

Summary: In pregnancies with placental insufficiency, the only available treatment is close monitoring to determine the point at which the risks of preterm birth for the baby are lower than the risks of continuing the pregnancy. Therefore, safely prolonging pregnancy is the current management goal for this condition. Statins, such as pravastatin, are approved and marketed drugs used to prevent cardiovascul...

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

Enrollment Status: Recruiting

Publish Date: February 13, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.

View All Clinical Trials